Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 2, 2012, Pages 283-290

  Nakamura, Keiichiro ^a   Joja, Ikuo ^b   Kodama, Junichi ^a   Hongo, Atsushi ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Magnetic resonance imaging; Maximum standardized uptake value; Minimum apparent diffusion coefficient; Positron emission tomography computed tomography; Predictor for poor prognosis

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIMARY TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; DIFFUSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MEDICAL ONCOLOGY; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84859635772     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1978-7     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. (Pubitemid 40372904)
2. Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, et al. Carcinoma of the cervix uteri. J Epidemiol Biostat. 2001;6(1):7-43.
3. Delgado G, Bundy BN, Fowler Jr WC, Stehman FB, Sevin B, Creasman WT, et al. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989;35(3):314-20. (Pubitemid 20025893)
4. Dudeck O, Zeile M, Pink D, Pech M, Tunn PU, Reichardt P, et al. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging. 2008;27(5):1109-13. (Pubitemid 351614624)
5. Guo AC, Cummings TJ, Dash RC, Provenzale JM. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology. 2002;224(1):177-83. (Pubitemid 34680392)
6. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology. 2003;226 (1):71-8. (Pubitemid 36163910)
7. Zhang J, Tehrani YM, Wang L, Ishill NM, Schwartz LH, Hricak H. Renal masses: characterization with diffusion-weighted MR imaging - a preliminary experience. Radiology. 2008;247(2):458-64.
8. Hayashida Y, Hirai T, Morishita S, Kitajima M, Murakami R, Korogi Y, et al. Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol. 2006;27(7):1419-25. (Pubitemid 44260120)
9. Kanauchi N, Oizumi H, Honma T, Kato H, Endo M, Suzuki J, et al. Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer. Eur J Cardiothorac Surg. 2009;35(4):706-10.
10. Taouli B, Thakur RK, Mannelli L, Babb JS, Kim S, Hecht EM, et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology. 2009;251 (2):398-407.
11. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007;188(6):1622-35. (Pubitemid 46866868)
12. Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed. 2009;22 (1):104-13.
13. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2(9):683-93. (Pubitemid 37328919)
14. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18] fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6(10):3837-44.
15. Buck A, Schirrmeister H, Kühn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29(10):1317-23. (Pubitemid 44392212)
16. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004;109(6):926-32. (Pubitemid 38500750)
17. Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol. 2001;176 (6):1449-54. (Pubitemid 32510262)
18. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol. 2001;82(1):17-21. (Pubitemid 32634948)
19. Mack MG, Rieger J, Baghi M, Bisdas S, Vogl TJ. Cervical lymph nodes. Eur J Radiol. 2008;66(3):493-500.
20. Nakamura K, Okumura Y, Kodama J, Hongo A, Kanazawa S, Hiramatsu Y. The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix. Gynecol Oncol. 2010;119 (1):81-6.
21. Boyce J, Fruchter RG, Nicastri AD, Ambiavagar PC, Reinis MS, Nelson Jr JH. Prognostic factors in stage I carcinoma of the cervix. Gynecol Oncol. 1981;12(2 Pt 1):154-65. (Pubitemid 12239321)
22. Burghardt E, Pickel H, Haas J, Lahousen M. Prognostic factors and operative treatment of stages IB to IIB cervical cancer. Am J Obstet Gynecol. 1987;156(4):988-96. (Pubitemid 17058817)
23. Van Bommel PF, Van Lindert AC, Kock HC, Leers WH, Neijt JP. A review of prognostic factors in early-stage carcinoma of the cervix (FIGO I B and II A) and implications for treatment strategy. Eur J Obstet Gynecol Reprod Biol. 1987;26(1):69-84. (Pubitemid 17136158)
24. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology. 2006;239(3):632-49. (Pubitemid 43830599)
25. Matsushima N, Maeda M, Takamura M, Takeda K. Apparent diffusion coefficients of benign and malignant salivary gland tumors. Comparison to histopathological findings. J Neuroradiol. 2007;34(3):183-9. (Pubitemid 47042899)
26. Abdel Razek AA, Soliman NY, Elkhamary S, Alsharaway MK, Tawfik A. Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol. 2006;16(7):1468-77. (Pubitemid 43871818)
27. Humphries PD, Sebire NJ, Siegel MJ, Olsen ∅E. Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology. 2007;245 (3):848-54.
28. Naganawa S, Sato C, Kumada H, Ishigaki T, Miura S, Takizawa O. Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix. Eur Radiol. 2005;15 (1):71-8. (Pubitemid 40109773)
29. McVeigh PZ, Syed AM, Milosevic M, Fyles A, Haider MA. Diffusion-weighted MRI in cervical cancer. Eur Radiol. 2008;18 (5):1058-64.
30. Paulino AC, Johnstone PA. FDG-PET in radiotherapy treatment planning: pandora's box? Int J Radiat Oncol Biol Phys. 2004;59 (1):4-5. (Pubitemid 38501500)
31. Fukui MB, Blodgett TM, Snyderman CH, Johnson JJ, Myers EN, Townsend DW, et al. Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics. 2005;25(4):913-30.
32. Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging. 2002;29 (12):1639-47.
33. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110(8):1738-44.
34. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18) fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20 (2):379-87.
35. Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998;39 (10):1727-35. (Pubitemid 28473521)
36. Ito K, Kato T, Ohta T, Tadokoro M, Yamada T, Ikeda M, et al. Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity. Eur J Nucl Med. 1996;23(10):1372-7. (Pubitemid 26340591)
37. Kim HS, Kim SY. A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas. AJNR Am J Neuroradiol. 2007;28 (9):1693-9. (Pubitemid 47598142)
38. Higano S, Yun X, Kumabe T, Watanabe M, Mugikura S, Umetsu A, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology. 2006;241(3):839-46. (Pubitemid 46190551)
39. Murakami R, Sugahara T, Nakamura H, Hirai T, Kitajima M, Hayashida Y, et al. Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology. 2007;243(2):493-9. (Pubitemid 46649706)
40. Ho KC, Lin G, Wang JJ, Lai CH, Chang CJ, Yen TC. Correlation of apparent diffusion coefficients measured by 3 T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging. 2009;36(2):200-8.